People with prediabetes or diabetes who live in smog-filled cities may be more prone to pulmonary fibrosis as a result of exposure to ozone, a study in mice indicates. The study, “Repetitive Ozone Exposures and Evaluation of Pulmonary Inflammation and Remodeling in Diabetic Mouse Strains,” was published…
Diabetes Raises Risk of Lung Scarring Due to Ozone Pollution, Study Suggests
Idiopathic pulmonary fibrosis (IPF) negatively affects a person’s health-related quality of life (HRQoL), especially their physical health, a review study suggests. Patients’ age and disease severity also were found to have an impact on HRQoL. The study, “Health-related quality of life of patients with idiopathic pulmonary fibrosis: a…
iBio has received a U.S. patent for its method of increasing the amount and quality of endostatin-derived peptides generated from the company’s plant-based FastPharming protein production system. These peptides, which have been shown to possess strong anti-fibrotic or anti-scarring properties, make up part of IBIO-100, an experimental…
We moved out of our house today. Tomorrow, my husband, Jonny, our two pets, and I will board a plane for a new life in a new place. We are leaving Washington state behind for good. While I am sad to leave my friends, closing this chapter feels like a…
The U.S. Food and Drug Administration (FDA) has granted treprostinil orphan drug designation for the treatment of idiopathic pulmonary fibrosis (IPF). Orphan drug designation is given to therapies with the potential to substantially improve treatment for rare diseases (conditions affecting fewer than 200,000 people in the U.S.). The designation…
I recently celebrated another birthday, my fourth since being diagnosed with idiopathic pulmonary fibrosis (IPF). Prior to adding “rare disease patient” to my list of personal identities, I never cared much about birthdays. Now, I embrace them and enjoy celebrating the year that has passed and looking forward to…
The global COVID-19 pandemic has had a negative local impact on healthcare for most people in the U.K. with pulmonary fibrosis (PF), who have seen their medical appointments canceled, their pulmonary rehabilitation programs halted, and their health status decline as a result of lockdowns and other safety measures,…
The nonprofit Three Lakes Foundation and the healthcare incubator MATTER announced the four winners of the 2020 Innovation Challenge, an initiative that promotes advancements in the way pulmonary fibrosis (PF) is diagnosed, treated, and managed. Winners of the challenge will receive a monetary award…
GLPG1205, an investigational therapy by Galapagos, was found to be safe and well tolerated, with an ability to lower lung function decline in adults with idiopathic pulmonary fibrosis (IPF), according to results from a Phase 2 clinical trial. Top-line data from the study, called PINTA (…
A Phase 3 clinical trial evaluating Bellerophon Therapeutics’ investigational therapy INOpulse — inhaled nitric oxide — in patients with pulmonary fibrosis (PF) at risk of developing pulmonary hypertension (PH) has enrolled its first patient. Top-line data from the trial, called REBUILD (NCT03267108), are expected by 2022. “We…
